Innoforce Pharmaceuticals Opens Analytical Development and Process Development Facility in Hangzhou, China

HANGZHOU and ROCKVILLE

August 16, 2021

Innoforce Pharmaceuticals ("Innoforce"), a biopharmaceutical innovation and partnership company, today announces that **it has opened a new Advanced Cell and Gene Therapy Development Facility in Hangzhou, China**. Analytical development (AD) and Process development (PD) represents a critical step towards providing services for potential clients in their cell & gene therapy product development to support clinical trials and further commercialization. Innoforce's development facility further strengthens the company's capability in analytical development, process characterization, validation, and staff training for a broad range of cell and gene products.

The facility is set up as an AD-PD development laboratory to provide analytical method development and qualification, quality control preparations, process development, and building platform technology approach in preparation for the launch of Innoforce's GMP manufacturing facility in 2022.

"The capability of analytical and process development largely dictates the success of any cell and gene therapy development. It is understood by all players in the industry that this is a critical aspect of cell and gene therapy product development. Innoforce's Development Facility aims to address the crucial need for quality and expertise in the Process and Analytical Development areas," commented **Yuling Li, CEO of Innoforce**.

The new facility significantly accelerates Innoforce’s ability to develop and deliver cost-effective, robust, scalable, analytical capability and processing technologies to drive client's programs' efficient and rapid progression to GMP manufacturing. Innoforce will provide end-to-end manufacturing services, including GMP commercial manufacturing of plasmid DNA, viral vector, and cell therapy products by the middle of 2022. Innoforce's new Development Facility is located at the ChuanHua Science and Technology Building, Xiaoshan Innovation Zone.

健新原力成功在杭州设立分析和工艺开发中心

中国杭州和美国 Rockville

2021 年 8 月 16 日

健新原力,一家专注于创新和伙伴合作的生物制药公司,今天宣布**在中国杭州设立了一个全新的先进细胞和基因治疗的分析和工艺开发中心**。分析开发 (AD) 和工艺开发 (PD) 是为潜在客户提供用以支持临床试验和进一步商业化的细胞和基因治疗产品开发服务的关键一步。健新原力的研发设备和人才投入进一步增强了公司在细胞和基因产品的分析开发、工艺特性、校验以及员工培训方面的能力。

本次设立的分析和工艺开发中心,主要用以提供分析方法开发和认证、质量控制准备、工艺开发以及为健新原力 2022 年 GMP 生产设施启动做准备,构建平台技术方法。

健新原力首席执行官李玉玲指出"分析和工艺开发的能力在很大程度上决定了任何细胞和基因治疗开发的成功与否。所有业内人士都明白,这是细胞和基因治疗产品开发的一个关键方面。健新原力设立该中心旨在满足工艺和分析开发领域对质量和专业知识的关键需求。"

新的中心极大地提升了健新原力开发和提供经济高效、稳健、可扩展分析能力的实力,以及能够推动客户项目高效、快速地向 GMP 制造迈进的工艺技术。健新原力将在 2022 年年中提供端到端的生产服务,其中包括质粒 DNA、病毒载体和细胞治疗产品的 GMP 商业化生产。该中心位于中国萧山科技城传化科创大厦。